25.27
3.94%
+0.935
AnaptysBio Inc stock is currently priced at $25.27, with a 24-hour trading volume of 241.69K.
It has seen a +3.94% increased in the last 24 hours and a +18.67% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $23.29 pivot point. If it approaches the $25.55 resistance level, significant changes may occur.
Previous Close:
$24.34
Open:
$24.38
24h Volume:
241.69K
Market Cap:
$687.61M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-4.8699
EPS:
-5.19
Net Cash Flow:
$-121.61M
1W Performance:
+31.29%
1M Performance:
+18.67%
6M Performance:
+52.96%
1Y Performance:
+19.51%
AnaptysBio Inc Stock (ANAB) Company Profile
Name
AnaptysBio Inc
Sector
Industry
Phone
858-362-6295
Address
10421 Pacific Center Court, Suite 200, San Diego, CA
AnaptysBio Inc Stock (ANAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
May-18-23 | Initiated | TD Cowen | Outperform |
Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
Sep-19-22 | Resumed | H.C. Wainwright | Buy |
Sep-13-22 | Downgrade | Truist | Buy → Hold |
Sep-01-22 | Initiated | Raymond James | Outperform |
Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
Jun-22-21 | Initiated | H.C. Wainwright | Buy |
May-21-21 | Initiated | UBS | Neutral |
Mar-16-21 | Upgrade | Truist | Hold → Buy |
Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
Jun-21-19 | Downgrade | Stifel | Buy → Hold |
Dec-20-18 | Initiated | H.C. Wainwright | Buy |
Nov-21-18 | Initiated | JP Morgan | Overweight |
Jul-19-18 | Initiated | Credit Suisse | Outperform |
Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Mar-27-18 | Reiterated | Stifel | Buy |
Mar-06-18 | Reiterated | Stifel | Buy |
Feb-15-18 | Reiterated | SunTrust | Buy |
Jan-23-18 | Reiterated | Credit Suisse | Outperform |
Nov-15-17 | Initiated | SunTrust | Buy |
Nov-09-17 | Initiated | Jefferies | Buy |
Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
AnaptysBio Inc Stock (ANAB) Latest News
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
Zacks Investment Research
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
The Motley Fool
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Benzinga
Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
Zacks Investment Research
Unveiling 4 Analyst Insights On AnaptysBio
Benzinga
AnaptysBio Inc Stock (ANAB) Financials Data
AnaptysBio Inc (ANAB) Revenue 2024
ANAB reported a revenue (TTM) of $17.16 million for the quarter ending December 31, 2023, a +66.78% rise year-over-year.
AnaptysBio Inc (ANAB) Net Income 2024
ANAB net income (TTM) was -$163.62 million for the quarter ending December 31, 2023, a -27.11% decrease year-over-year.
AnaptysBio Inc (ANAB) Cash Flow 2024
ANAB recorded a free cash flow (TTM) of -$121.61 million for the quarter ending December 31, 2023, a -64.44% decrease year-over-year.
AnaptysBio Inc (ANAB) Earnings per Share 2024
ANAB earnings per share (TTM) was -$6.08 for the quarter ending December 31, 2023, a -33.04% decline year-over-year.
AnaptysBio Inc Stock (ANAB) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Faga Daniel | CEO |
Mar 22 '24 |
Sale |
22.78 |
145,940 |
3,325,185 |
752,087 |
LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Feb 16 '24 |
Option Exercise |
14.02 |
5,000 |
70,100 |
8,240 |
LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Feb 16 '24 |
Sale |
25.00 |
5,000 |
125,000 |
3,240 |
MULROY DENNIS | CHIEF FINANCIAL OFFICER |
Jan 30 '24 |
Sale |
23.63 |
3,065 |
72,425 |
964 |
Faga Daniel | CEO |
Jan 08 '24 |
Sale |
21.81 |
6,866 |
149,747 |
898,027 |
Lizzul Paul F. | Chief Medical Officer |
Jan 08 '24 |
Sale |
21.81 |
2,554 |
55,703 |
10,118 |
LOUMEAU ERIC J | Chief Legal Officer |
Jan 08 '24 |
Sale |
21.81 |
2,305 |
50,272 |
3,240 |
MULROY DENNIS | Chief Financial Officer |
Jan 08 '24 |
Sale |
21.81 |
2,180 |
47,546 |
4,029 |
LOUMEAU ERIC J | Chief Legal Officer |
Jan 06 '24 |
Option Exercise |
0.00 |
5,545 |
0 |
5,545 |
Lizzul Paul F. | Chief Medical Officer |
Jan 06 '24 |
Option Exercise |
0.00 |
6,145 |
0 |
12,672 |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
Cap:
|
Volume (24h):